Myriad Genetics Plummets 20% As UnitedHealth Changes GeneSight Coverage
Stephens analyst mason carrico notes that myriad genetics (mygn) shares are down about 20% this morning, which the firm blames on an announcement from unitedhealth. Genesight® pharmacogenomics test volumes grew 19%. Myriad genetics reports second quarter 2023 financial results and reaffirms 2023 revenue and adjusted eps guidance; Generates the fourth consecutive. Second quarter saw continued payer coverage wins including a recent decision by blue shield of california to follow the state's biomarker law and add genesight to its medical policy for.
1, 2024, 10:20 am. Piper sandler thinks myriad genetics (mygn), which has seen its shares fall nearly 22% on friday morning, is trading down on a coverage.